2,6-bis[2,6-bis(tert-butylamino)hexanoylamino]-N-[5-[[6-[2,6-bis(tert-butylamino)hexanoylamino]-2-[4-[4-(tert-butylamino)butyl]-2,2-dimethyl-5-oxoimidazolidin-1-yl]hexanoyl]amino]-6-[2-(2-methoxyethoxy)ethylamino]-6-oxohexyl]hexanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,6-bis[2,6-bis(tert-butylamino)hexanoylamino]-N-[5-[[6-[2,6-bis(tert-butylamino)hexanoylamino]-2-[4-[4-(tert-butylamino)butyl]-2,2-dimethyl-5-oxoimidazolidin-1-yl]hexanoyl]amino]-6-[2-(2-methoxyethoxy)ethylamino]-6-oxohexyl]hexanamide
• 化学式: C₇₈H₁₅₇N₁₅O₉
• 分子量: 1449.2
• InChiKey: USEWJIDTSHCXLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  102
• 可旋转键数：
  60
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  310
• 氢给体数：
  14
• 氢受体数：
  17

文献信息

• Polymeric Hyperbranched Carrier-Linked Prodrugs
  申请人：Hersel Ulrich

  公开号：US20140243254A1

  公开（公告）日：2014-08-28

  The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein POL is a polymeric moiety, each Hyp is independently a hyperbranched moiety, each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs and methods of treatment.
• US9561287B2
  申请人：——

  公开号：US9561287B2

  公开（公告）日：2017-02-07